Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
63
BDX Quote, Financials, Valuation and Earnings
Last price:
$202.69
Seasonality move
:
3.89%
Day range:
$201.40 - $206.37
52-week range:
$162.29 - $251.99
Dividend yield:
2.06%
P/E ratio:
34.78x
P/S ratio:
2.67x
P/B ratio:
2.28x
Volume:
1.3M
Avg. volume:
1.8M
1-year change:
-13.51%
Market cap:
$57.9B
Revenue:
$21.8B
EPS (TTM):
$5.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$5.2B | $2.81 | -0.31% | 169.42% | $206.67 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.50 | 8.1% | 61.63% | $144.75 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.5% | 76.25% | $125.45 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.71 | 8.96% | 16.17% | $291.80 |
|
SOLV
Solventum Corp.
|
$2B | $1.50 | -5.45% | 768.77% | $87.18 |
|
WST
West Pharmaceutical Services, Inc.
|
$795.7M | $1.83 | 6.25% | 3.35% | $345.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$202.75 | $206.67 | $57.9B | 34.78x | $1.05 | 2.06% | 2.67x |
|
ABT
Abbott Laboratories
|
$125.92 | $144.75 | $219B | 15.79x | $0.59 | 1.87% | 5.02x |
|
BSX
Boston Scientific Corp.
|
$97.64 | $125.45 | $144.7B | 52.23x | $0.00 | 0% | 7.53x |
|
RMD
ResMed, Inc.
|
$252.47 | $291.80 | $36.9B | 25.84x | $0.60 | 0.9% | 7.07x |
|
SOLV
Solventum Corp.
|
$86.14 | $87.18 | $14.9B | 9.92x | $0.00 | 0% | 1.79x |
|
WST
West Pharmaceutical Services, Inc.
|
$275.52 | $345.71 | $19.8B | 40.81x | $0.22 | 0.31% | 6.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.449 | 37.48% | 0.47x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | 5.99% | 1.12x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
RMD
ResMed, Inc.
|
12.15% | 0.549 | 2.12% | 1.89x |
|
SOLV
Solventum Corp.
|
50.75% | 0.850 | 40.57% | 0.94x |
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.594 | 1.61% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
Becton, Dickinson & Co. vs. Competitors
-
Which has Higher Returns BDX or ABT?
Abbott Laboratories has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 14.07%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About BDX or ABT?
Becton, Dickinson & Co. has a consensus price target of $206.67, signalling upside risk potential of 1.93%. On the other hand Abbott Laboratories has an analysts' consensus of $144.75 which suggests that it could grow by 14.95%. Given that Abbott Laboratories has higher upside potential than Becton, Dickinson & Co., analysts believe Abbott Laboratories is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 ABTAbbott Laboratories15 7 0 -
Is BDX or ABT More Risky?
Becton, Dickinson & Co. has a beta of 0.236, which suggesting that the stock is 76.383% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock BDX or ABT?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.06%. Abbott Laboratories offers a yield of 1.87% to investors and pays a quarterly dividend of $0.59 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or ABT?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Becton, Dickinson & Co.'s net income of $493M is lower than Abbott Laboratories's net income of $1.6B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 34.78x while Abbott Laboratories's PE ratio is 15.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.67x versus 5.02x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.67x 34.78x $5.9B $493M ABTAbbott Laboratories5.02x 15.79x $11.4B $1.6B
-
Which has Higher Returns BDX or BSX?
Boston Scientific Corp. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 14.91%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About BDX or BSX?
Becton, Dickinson & Co. has a consensus price target of $206.67, signalling upside risk potential of 1.93%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.45 which suggests that it could grow by 28.48%. Given that Boston Scientific Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Boston Scientific Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 BSXBoston Scientific Corp.25 2 0 -
Is BDX or BSX More Risky?
Becton, Dickinson & Co. has a beta of 0.236, which suggesting that the stock is 76.383% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock BDX or BSX?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.06%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or BSX?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Becton, Dickinson & Co.'s net income of $493M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 34.78x while Boston Scientific Corp.'s PE ratio is 52.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.67x versus 7.53x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.67x 34.78x $5.9B $493M BSXBoston Scientific Corp.7.53x 52.23x $5.1B $755M
-
Which has Higher Returns BDX or RMD?
ResMed, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 26.1%. Becton, Dickinson & Co.'s return on equity of 6.6% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About BDX or RMD?
Becton, Dickinson & Co. has a consensus price target of $206.67, signalling upside risk potential of 1.93%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 15.58%. Given that ResMed, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe ResMed, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 RMDResMed, Inc.8 7 1 -
Is BDX or RMD More Risky?
Becton, Dickinson & Co. has a beta of 0.236, which suggesting that the stock is 76.383% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.416%.
-
Which is a Better Dividend Stock BDX or RMD?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.06%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or RMD?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Becton, Dickinson & Co.'s net income of $493M is higher than ResMed, Inc.'s net income of $348.5M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 34.78x while ResMed, Inc.'s PE ratio is 25.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.67x versus 7.07x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.67x 34.78x $5.9B $493M RMDResMed, Inc.7.07x 25.84x $1.3B $348.5M
-
Which has Higher Returns BDX or SOLV?
Solventum Corp. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 60.4%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About BDX or SOLV?
Becton, Dickinson & Co. has a consensus price target of $206.67, signalling upside risk potential of 1.93%. On the other hand Solventum Corp. has an analysts' consensus of $87.18 which suggests that it could grow by 1.21%. Given that Becton, Dickinson & Co. has higher upside potential than Solventum Corp., analysts believe Becton, Dickinson & Co. is more attractive than Solventum Corp..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 SOLVSolventum Corp.3 7 1 -
Is BDX or SOLV More Risky?
Becton, Dickinson & Co. has a beta of 0.236, which suggesting that the stock is 76.383% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDX or SOLV?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.06%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or SOLV?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Becton, Dickinson & Co.'s net income of $493M is lower than Solventum Corp.'s net income of $1.3B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 34.78x while Solventum Corp.'s PE ratio is 9.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.67x versus 1.79x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.67x 34.78x $5.9B $493M SOLVSolventum Corp.1.79x 9.92x $2.1B $1.3B
-
Which has Higher Returns BDX or WST?
West Pharmaceutical Services, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 17.41%. Becton, Dickinson & Co.'s return on equity of 6.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B -
What do Analysts Say About BDX or WST?
Becton, Dickinson & Co. has a consensus price target of $206.67, signalling upside risk potential of 1.93%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 25.48%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 WSTWest Pharmaceutical Services, Inc.11 3 0 -
Is BDX or WST More Risky?
Becton, Dickinson & Co. has a beta of 0.236, which suggesting that the stock is 76.383% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.
-
Which is a Better Dividend Stock BDX or WST?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.06%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or WST?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Becton, Dickinson & Co.'s net income of $493M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 34.78x while West Pharmaceutical Services, Inc.'s PE ratio is 40.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.67x versus 6.65x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.67x 34.78x $5.9B $493M WSTWest Pharmaceutical Services, Inc.6.65x 40.81x $804.3M $140M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
